IMPAX Laboratories, Inc. announced that the US Food and Drug Administration (FDA) has granted tentative approval for its generic version of Tricor® (Fenofibrate) Tablets, according to Biospace.com. The introduction of generic Tricor tablets, which are designed to help patients control their cholesterol levels, demonstrates how the lucrative cardiovascular therapy market is becoming more competitive due to new product introductions and patent expirations.

Americans’ propensity for high-cholestero, high-fat foods has led to a lucrative opportunity for pharmaceutical companies in the arena of cardiovascular treatment. Approximately 15 million people in the United States will require cardiovascular treatment this year, according to the American Heart Association. This translates into a substantial market that offers opportunities for both new blockbusters and generic competitiors.

“The cardiovascular market presents the largest opportunity for pharmaceutical companies to launch blockbuster products,” said Elio Evangelista, senior analyst at Cutting Edge Information. “Pharmaceutical leaders are increasingly competing with generics companies on post-patent treatment.”

The environment of an expanding market coupled with the patent expirations of blockbuster drugs has led to the flooding of the market with generics. Cutting Edge Information analyzes the strategies companies employ to combat generics competition and increase profits.

“Cardiovascular Marketing: Budgets, Staffing and Strategy,” (http://www.PharmaCardio.com) Cutting Edge Information’s latest report, analyzes innovative marketing strategies available to cardiovascular brand teams and resource allocation levels and practices of leading pharmaceutical companies such as Pfizer, Novartis and Aventis.  With metrics and detailed case studies, the report explores portfolio prioritization, innovative marketing, and evolving industry trends.        

To download a free summary of “Cardiovascular Marketing: Budgets, Staffing and Strategy,” visit http://www.PharmaCardio.com.  For more information on this report or to learn about other research being conducted by Cutting Edge Information, contact Diana Borja at diana_borja@cuttingedgeinfo.com or 919-433-0219. 

 
<-- Back to the News Page

<-- Back to the Cutting Edge Information home page